Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Plans $127 Million US IPO in February

publication date: Jan 20, 2016
BeiGene, an innovative biopharma located in Beijing, hopes to raise $126.5 million in its NASDAQ IPO, currently scheduled to take place in the first week of February. BeiGene is a cancer-focused company that develops molecularly targeted and immuno-oncology drugs. The IPO values six-year-old BeiGene at close to $900 million. The company, which has four drug candidates in Phase I trials, is facing a cautious market after several years of very positive biopharma IPO conditions. Two of BeiGene's venture backers indicated they might like to buy 50% of the offering. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital